Search results

Skip to results

Type

Status

Last updated

Showing 1 to 4 of 4 results for posaconazole

  1. Ivosidenib with azacitidine for untreated acute myeloid leukaemia with an IDH1 R132 mutation (TA979)

    Evidence-based recommendations on ivosidenib (Tibsovo) with azacitidine for untreated acute myeloid leukaemia with an IDH1 R132 mutation.

    Technology appraisal guidance
    Published
    5 June 2024
    View recommendations

    Sections for TA979

  2. What are the clinical and cost effectiveness, and the safety, of specific antifungal treatments for treating suspected or confirmed COVID-19-associated pulmonary aspergillosis (CAPA), and the optimal treatment duration? When should treatment be started, stopped or modified?

    COVID-19. I: voriconazole, isavuconazole, liposomal amphotericin B, posaconazole, echinocandins (for example, caspofungin,...

    Research recommendation
    Published
    9 March 2022

  3. Venetoclax with azacitidine for untreated acute myeloid leukaemia when intensive chemotherapy is unsuitable (TA765)

    Evidence-based recommendations on venetoclax (Venclyxto) with azacitidine for untreated acute myeloid leukaemia in adults when intensive chemotherapy is unsuitable.

    Technology appraisal guidance
    Published
    2 February 2022
    View recommendations

    Sections for TA765

  4. Venetoclax with low dose cytarabine for untreated acute myeloid leukaemia when intensive chemotherapy is unsuitable (TA787)

    Evidence-based recommendations on venetoclax (Venclyxto) with low dose cytarabine for untreated acute myeloid leukaemia in adults when intensive chemotherapy is unsuitable.

    Technology appraisal guidance
    Published
    27 April 2022
    View recommendations

    Sections for TA787